within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CF02_Cloxacillin;

model Cloxacillin_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.37,
    Cl = 1.972222222222222e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0009,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cloxacillin_1</td></tr><tr><td>ATC code:</td><td>J01CF02_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cloxacillin is a beta-lactam antibiotic of the penicillinase-resistant penicillin class. It is mainly used for the treatment of infections caused by penicillinase-producing staphylococci, particularly skin, respiratory tract, bone, and joint infections. Cloxacillin is approved for clinical use and remains a recommended choice for staphylococcal infections in many guidelines.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of cloxacillin after oral administration in healthy adult volunteers (mixed sexes).</p><h4>References</h4><ol><li><p>Yin, OQ, et al., &amp; Chow, MS (2009). Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men. <i>Clinical therapeutics</i> 31(5) 999–1006. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2009.05.014\">10.1016/j.clinthera.2009.05.014</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19539100/\">https://pubmed.ncbi.nlm.nih.gov/19539100</a></p></li><li><p>Heimdahl, A, et al., &amp; Nord, CE (1988). A micromethod for determination of antimicrobial agents in bone. <i>Drugs under experimental and clinical research</i> 14(10) 649–654. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3246209/\">https://pubmed.ncbi.nlm.nih.gov/3246209</a></p></li><li><p>Middleton, RS, &amp; Sinha, HK (1979). Magnapen treatment of infections in the elderly. <i>The Journal of international medical research</i> 7(1) 52–56. DOI:<a href=\"https://doi.org/10.1177/030006057900700108\">10.1177/030006057900700108</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/421965/\">https://pubmed.ncbi.nlm.nih.gov/421965</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01CF02_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cloxacillin_1;
